|Bid||2.0400 x 4000|
|Ask||2.0500 x 3200|
|Day's range||1.9600 - 2.0600|
|52-week range||0.5600 - 3.6600|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Gamida Cell Ltd. ( NASDAQ:GMDA ) is possibly approaching a major achievement in its business, so we would like to shine...
Gamida Cell Ltd. ( NASDAQ:GMDA ) insiders who purchased shares in the last 12 months were richly rewarded last week...
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
Key Insights The considerable ownership by retail investors in Gamida Cell indicates that they collectively have a...
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Please be advised that this call is being recorded at Gamida Cell's request. Now, I would like to introduce your host for today's conference, Heather DiVecchia, Gamida Cell's director of investor relations and corporate communications. Welcome to today's call during which we will provide an update on the company and review our financial results for the second quarter of 2022.
The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...